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Abstracts / Urological Science 27 (2016) S36eS52 S49signiﬁcant improvement of PPBC at 1st and 3rd month compared with
baseline in younger group (P<0.05). In older group, the score of QoL and
OABSS were signiﬁcantly decreased at 1st and 3rd month compared with
baseline. (P<0.05).The mean changes of most measurements after 3
months of treatment were no signiﬁcant difference between younger and
older patients, except Qmax and voided volume. Younger patients expe-
rience more AEs than the elders (26.79% vs 12.5%) during treatment. The
common AEs included dry mouth (n¼5), abdominal distension (n¼3) and
dizziness (n¼3). Nevertheless, the incidence of AEs when using mirabe-
gron were acceptable low in two groups.
Conclusion: Mirabegron 25 mg once daily is a safe and effective drug to
improve OAB symptoms and QoL in old patients with multiple comor-
bidities. The treatment efﬁcacy were no much difference between younger
and older patients.
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Purpose: To evaluate subjective symptoms improvement of Silodosin
treatment for BPH patients with unsatisfactory response to initial ɑ1
blocker.
Materials and Methods: 50 patients diagnosed with BPH and reported
with unsatisfactory response to initial ɑ1 blocker were included in this
study. IPSS were recorded before and after administration of 4 weeks of
Silodosin. No drug withdrawal period was provided when switching the
drug. We evaluate subjective improvement of Silodosin treatment ac-
cording to the International Prostate Symptom Score.
Results: 28 patients (56 %) had subjective improvement according to the
International Prostate Symptom Score total score but 22 patients failed to
have symptoms improvement. Comparison of symptoms revealed that
Silodosin showed signiﬁcant effect on nocturia. The most frequent adverse
drug reaction was ejaculatory disorder with Silodosin.
Conclusion: Silodosin exhibits some efﬁcacy in improving subjective
symptoms especially in nocturia for BPH patients with unsatisfactory
response to initial ɑ1 blocker
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Purpose: When considering antimuscarinics for patients with overactive
bladder (OAB), post-void residual urine volume (PVR) is an important
factor for decision-making. Using antimuscarinics in patients with a large
amount PVR is not desirable. It is a reasonable inference that patients with
good ﬂow rates should be able to empty their bladders to achieve a low
PVR. If this hypothesis is correct, then antimuscarinics can be used safely in
OAB patients with good ﬂow rate without the need to check PVR. This
study tested this hypothesis by evaluating the correlation between uroﬂow
rate and PVR in men with OAB symptom.
Materials and Methods: We retrospectively recruited male OAB patients,
who had urgency with or without urge incontinence, between Aug 2008
and July 2015. Exclusion criteria included urinary tract infection, prostate
and bladder cancer. Patients with abdominal strain pattern or inadequate
voided volume (less than 150ml) on uroﬂowmetry (UFR) were excluded.
Patients were categorized into good Qmax and low Qmax groups by the
cut-off value of 15ml/sec maximal ﬂow rate (Qmax) in free uroﬂowmetry.
All patients received pressure ﬂow studies for evaluating bladder outlet
obstruction (BOO) and transabdominal ultrasonography for evaluating the
prostatic size, intra-vesical prostatic protrusion (IPP) and detrusor wall
thickness (DWT). BOO was deﬁned by BOOI>40. Amounts of residual urinewere determined by post-void catheterization. International Prostate
Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS)
were collected for symptom evaluation.
Results: A total of 136 male patients with OAB symptoms were enrolled.
The patients’ demographic was showed in table 1. Patients with good
Qmax group were signiﬁcantly younger. Patients with good Qmax had
lower scores in the total score of IPSS and voiding subscore. Nocturia as
evaluated by IPSS and OABSS was more severe in patients with low Qmax
group. PVR in good Qmax group was signiﬁcantly less than that in low
Qmax group (49.3±39.0 vs 82.7±79.6, p¼0.04). However, in good Qmax
group, 15.7% patients had PVR more than 100ml and 7.1% had PVR more
than 200ml. More patients in low Qmax group had BOO than those in good
Qmax group (48.6% vs 24.2%, p¼0.03)
Conclusion: Male OAB patients with maximal uroﬂow rate higher than
15ml/sec have lower PVR. Nevertheless, clinical signiﬁcant high PVRmight
still present in patients with good ﬂow rate. It is still necessary to measure
PVR even in patients with a satisfactory uroﬂow rate.
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Purpose: To assess the safety and efﬁcacy of the treatments performed
with low-intensity extracorporeal shockwave therapy (LI-ESWT) on
symptomatic chronic pelvic pain syndrome (CPPS) patients.
Materials and Methods: We design a prospective, blind and randomized
controlled trial for patients with CPPS. All patients have once LI-ESWT per
week for 4 weeks. Use questionnaire of pre-treatment and post-treatment
to assess the safety and efﬁcacy.
Results: The National Institutes of Health Chronic Prostatitis Symptom
Index (NIH-CPSI) scores, especially CPSI pain domain, of enrolled patient
were improved after 4 times LI-ESWT. More than half patients who got LI-
ESWT had symptomatic improvement after ﬁst treatment. There is a ten-
dency to improve sexual quality after full therapeutic regimen. No patients
have ecchymosis, intolerable pain or other complication during LI-ESWT.
Conclusion: We describe our experience of LI-ESWT for CPPS patients. In
this pilot study, LI-ESWT can improve quality of life for CPPS patients
without complications.
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Purpose: Despite increasing application of high-intensity focused ultra-
sound (HIFU), there was few published experience regarding to salvage
management for recurrent localized prostate cancer. We aim to evaluate
tolerance and oncologic control with salvage radiotherapy (SRT) after HIFU
failure and to identify predictive factors of success.
Materials and Methods: In this single-centre retrospective study, retro-
spective analysis on 121 localized prostate cancer patients status post the
HIFU therapy from December 2009 to July 2015 were performed with
perioperative data. Total 11 patients underwent salvage radiotherapy with
dose ranging from 2400-7200 cGy. The median dose of conformal treat-
ment was 7000 cGy. The primary outcome measure was progression-free
